Rosalinda H. Arends

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

Myron J. Levin, Andrew Ustianowski, Stéphane De Wit et al. · Open Forum Infectious Diseases · 2021 · 34 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +16

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

Rosalinda H. Arends, Xiang Guo, Paul Baverel et al. · OncoImmunology · 2021 · 15 citations · Full text

Medicine, Immunology, Oncology +17

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends et al. · medRxiv · 2021 · 12 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14